XTL Biopharmaceuticals Ltd.
XTLB | TA
Overview
Corporate Details
- ISIN(s):
- IL0010854979
- LEI:
- 529900NDDXEAPTUTXP41
- Country:
- Israel
- Address:
- 5 HaCharoshet St., 4365603 Raanana
- Website:
- https://www.xtlbio.com
- Sector:
- Health Care
- Industry:
- Biotechnology
Description
XTL Biopharmaceuticals Ltd. focuses on the development of innovative therapeutics for the treatment of unmet medical needs in Israel.
Market Data
Market Data Not Available
Last Price
Change / %
Market Cap
N/A
Volume
Day High
Day Low
52W High
52W Low
Financials & KPIs
No data available
No Financial Data Available
Standardized financial statements for the selected period are not yet available.
Filings
Chat, Summarize & Extract with AI!
You have of free filing views remaining.
Upgrade for unlimited access.
| Date | Filing | Language | Size | Actions |
|---|---|---|---|---|
| 2025-07-29 08:54 |
Regulatory News Service
Immediate Report
|
English | 110.3 KB | |
| 2025-07-29 08:54 |
Regulatory News Service
Immediate Report
|
English | 36.4 KB | |
| 2025-07-24 00:45 |
Takeover Announcement Report
Immediate Report
|
English | 112.7 KB | |
| 2025-07-24 00:45 |
Regulatory News Service
Immediate Report
|
English | 36.4 KB | |
| 2025-06-15 11:36 |
Board/Management Change
Immediate Report of Meeting to be held on July 21, 2025
|
English | 735.8 KB | |
| 2025-06-15 11:36 |
Foreign Filer Report
Immediate Report of Meeting to be held on July 21, 2025
|
English | 262.4 KB | |
| 2025-06-15 11:36 |
Declaration of Voting Results & Voting Rights Announcements
Immediate Report of Meeting to be held on July 21, 2025
|
English | 131.2 KB | |
| 2025-05-01 01:18 |
Annual Report
FORM 20-F For the fiscal year ended December 31, 2024
|
English | 5.4 MB | |
| 2025-05-01 01:18 |
Foreign Filer Report
FORM 20-F For the fiscal year ended December 31, 2024
|
English | 36.3 KB | |
| 2025-04-07 18:27 |
Board/Management Change
Noam Band was appointed the Chief Executive Officer, Mr. Band replaces Shlomo S…
|
English | 141.8 KB | |
| 2025-04-07 18:27 |
Foreign Filer Report
Noam Band was appointed the Chief Executive Officer, Mr. Band replaces Shlomo S…
|
English | 36.3 KB | |
| 2025-03-04 14:39 |
Takeover Announcement Report
Definitive Exclusive Sublicense Agreement with Biossil, a company incorporated …
|
English | 116.4 KB | |
| 2025-03-04 14:39 |
Foreign Filer Report
Definitive Exclusive Sublicense Agreement with Biossil, a company incorporated …
|
English | 36.3 KB | |
| 2025-02-04 00:17 |
Takeover Announcement Report
. Tal Klinger’s and Yair Redl’s decisions to resign from the Board were not due…
|
English | 111.2 KB | |
| 2025-02-04 00:17 |
Foreign Filer Report
. Tal Klinger’s and Yair Redl’s decisions to resign from the Board were not due…
|
English | 36.3 KB |
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
| Company | Country | Ticker | View | |
|---|---|---|---|---|
|
1NKEMIA | Spain | IKM | |
|
2cureX AB | Sweden | 2CUREX | |
|
4SC AG | Germany | VSC | |
|
Abera Bioscience AB | Sweden | ABERA | |
|
ABIONYX Pharma | France | ABNX | |
|
Abliva | Sweden | ABLI | |
|
AB Science | France | AB | |
|
Acticor Biotech | France | ALACT | |
|
Active Biotech | Sweden | ACTI | |
|
AcuCort AB | Sweden | ACUC |